Product Images Losartan Potassium Tablets, 50 Mg

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Losartan Potassium Tablets, 50 Mg NDC 71610-418 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Bottle Label 25 mg - 71610 0417 45

Bottle Label 25 mg - 71610 0417 45

Bottle Label 50 mg - 71610 0418 45

Bottle Label 50 mg - 71610 0418 45

Aphena Pharma Solutions - TN - Aphena

Aphena Pharma Solutions - TN - Aphena

Figure 1 - figure1

Figure 1 - figure1

Figure 2 - figure2

Figure 2 - figure2

The text is describing a study comparing the efficacy of Atenolol and Losartan Potassium in reducing the risk of stroke in patients. The study found that Losartan Potassium had a 25% adjusted risk reduction compared to Atenolol, with a p-value of 0.001. The data is presented over the course of several months.*

Figure 3 - figure3

Figure 3 - figure3

The text appears to be a table showing primary endpoint events within demographic subgroups for Losartan and Atenolol. The demographic subgroups are based on age, gender, race, diabetes, and history of CVD. The table provides information such as the number of events, percentage rate, and hazard ratio with a confidence interval. The table includes symbols that are proportional to the sample sizes within each subgroup. There is not enough information in this text to determine the purpose or context of this table.*

Figure 4.jpg - figure4

Figure 4.jpg - figure4

This appears to be a clinical trial result or a research data table. The data shows that 80 patients (presumably female, based on the "F" next to the number) had an event. The "Risk Reduction" is 16.1%. The drug being tested is Losartan Potassium and it is being compared to a placebo, with the results being shown at the 12 and 24-week marks. Beyond that, there is not enough information to provide a more meaningful description or interpretation of the data.*

Losartan potassium, USP - structure

Losartan potassium, USP - structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.